The Programme

CI in a research-driven pharmaceutical company: is there anything besides competitive technical intelligence?

• Tracking pipelines for R&D and commercial success
• If science is the product, what is the "sizzle?"
• Organization, collaboration, and maintaining focus

Examining generic developments in the US and EU

• A primer on generic industry market dynamics
• Roche-Bolar and Hatch-Waxman review
• The generic industry portfolio management process
• EU generic industry dynamics

War gaming: a CI analysis tool for anticipating competitor actions

• Game theory and business: testing beliefs and assumptions about the pharma business environment
• Applying game theory suggestions to CI
• Identifying when to run strategy games
• The benefits of game theory on decision making and business development      

Generic defense for a big pharma company by reducing or neutralizing supply-side risk

• Assessment of the likely generic sources and levels of competition to the product in the coming years
• Measuring a supply-side strategy on how to best counteract competition threat
• Undertaking secondary and primary CI (in Eastern Europe, Asia and Latin America)  to assess the likely market attractiveness for generic competition
• Developing a proprietary rating system based on generic capability and intent to supply

Lunch and Keynote Presentation

Has pharma lost touch with reality? Wanted: more feet on the street

• Big pharma CI: swimming in data and over-analyzing old information  
• Assessing how every pharma/biotech can become world class
• Identifying the stumbling blocks and understanding how they can be overcome
• Reporting on some of the latest findings from a unique and ongoing global benchmarking study
• Who is doing what right in pharma and how to fix what’s currently broken

Exploring new and existing tools for information gathering and analysis

• A review of the most frequently used tools
• Attempting to justify the limited use of internal secondary sources
• Gathering international CI on the web
• Sharing resources with external CI groups
• Public data and customized research: exploring alternatives and in-betweens
• Benchmarking your CI initiatives

Automated, real-time CI: combining structured, unstructured and web data

• Using technology to merge data across digital sources in real-time
• Holistic view of single entities: drug, disease, competitor and more
• Drug pipeline observation and CI
• Technology, patent and regulatory watch
• Sales and marketing: launch, adverse events, price comparisons and prospect lists

Applying text analytics to the patent literature to gain competitive insight

• Text analytics, key element for decision-making process: understanding why and how to speed up patent portfolios analysis
• Managing and converting patent literature into actionable knowledge: information extraction and retrieval methods

Integrating CI into the organization

• Reporting structure
• Identifying where CI fits into the company
• Collaboration with independence: acknowledging CI as a unique discipline to market research
• Building an internal CI network
  Vehicles for communicating intelligence: gathering and disseminating 

The predictive value of thought leader insight

• Discussing the strengths and limitations of medical thought leader panels
• Sharing strategies for optimizing predictive value
• Case studies

The increasing need for total market forecasting

• Reviewing the latest forecasting techniques in pharma
• Accurately predicting future developments to facilitate decision-making strategies
• Choosing when to use patient flow analysis to solve problems
• Exercising forecasting techniques effectively for CI

Intelligence-guided differentiation strategies of inline and emerging products in a new and often uninformed hostile environment

• Continuous intelligence assessment of the ever-changing environmental pressures
• Positioning strategies of inline and emerging products in light of anticipated environmental horizon
• Identifying new products’ opportunities for existing markets or new market opportunities of existing products
• Leveraging the knowledge continuum to secure a flowing and a competitively viable product pipeline

Strategic decision-making and the role of CI

• The strategic internal positioning of CI: understanding why and where CI fits in
• Ensuring that knowledge is captured and transferred throughout the organization
• Using CI to implement strategy

Michael Fuller
Analyst
Nerac
Irene Zajac
Analyst
Nerac

Using patenting trends as CI to predict the future of drug discovery in the pharmaceutical and biotech industries

• Utilizing patent analytics to compare traditional big pharmacy with biotech
• What are the patent strategy differences between big pharma and biotech?
• How does recent patent activity correlate to the industry trends?
• How does this activity relate to the potential pipeline for pharmacy and biotech
• Retrospective look at patenting activity by IPC code since 2003
• Discussion using case study methodology: Pfizer and Amgen

Assessing the strategic impact of CI on business development

• How CI impacts and contributes to the licensing process.
• Focusing on how companies can create and maximize CI to help them make better and faster decisions during the licensing and M&A process
• Looking at the resources needed to undertake this effort